These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 16638874)
1. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874 [TBL] [Abstract][Full Text] [Related]
2. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Zhang H; Stephens LC; Kumar R Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771 [TBL] [Abstract][Full Text] [Related]
3. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379 [TBL] [Abstract][Full Text] [Related]
4. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Ma PC; Schaefer E; Christensen JG; Salgia R Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682 [TBL] [Abstract][Full Text] [Related]
5. Transgenic Polyoma middle-T mice model premalignant mammary disease. Maglione JE; Moghanaki D; Young LJ; Manner CK; Ellies LG; Joseph SO; Nicholson B; Cardiff RD; MacLeod CL Cancer Res; 2001 Nov; 61(22):8298-305. PubMed ID: 11719463 [TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Liu M; Howes A; Lesperance J; Stallcup WB; Hauser CA; Kadoya K; Oshima RG; Abraham RT Cancer Res; 2005 Jun; 65(12):5325-36. PubMed ID: 15958580 [TBL] [Abstract][Full Text] [Related]
7. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland. Torres-Arzayus MI; Yuan J; DellaGatta JL; Lane H; Kung AL; Brown M Cancer Res; 2006 Dec; 66(23):11381-8. PubMed ID: 17145884 [TBL] [Abstract][Full Text] [Related]
8. Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. Bon G; Folgiero V; Bossi G; Felicioni L; Marchetti A; Sacchi A; Falcioni R Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3280-7. PubMed ID: 16740748 [TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Nozawa H; Watanabe T; Nagawa H Cancer Lett; 2007 Jun; 251(1):105-13. PubMed ID: 17175097 [TBL] [Abstract][Full Text] [Related]
10. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling. Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710 [TBL] [Abstract][Full Text] [Related]
11. Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with Id-1 expression. Huh JI; Calvo A; Charles R; Green JE Cancer Res; 2006 Apr; 66(7):3495-503. PubMed ID: 16585173 [TBL] [Abstract][Full Text] [Related]
12. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation. Rupertus K; Dahlem C; Menger MD; Schilling MK; Kollmar O Ann Surg Oncol; 2009 Sep; 16(9):2629-37. PubMed ID: 19551445 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Moreno A; Akcakanat A; Munsell MF; Soni A; Yao JC; Meric-Bernstam F Endocr Relat Cancer; 2008 Mar; 15(1):257-66. PubMed ID: 18310292 [TBL] [Abstract][Full Text] [Related]
14. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. Chang SB; Miron P; Miron A; Iglehart JD J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887 [TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ. Namba R; Maglione JE; Young LJ; Borowsky AD; Cardiff RD; MacLeod CL; Gregg JP Mol Cancer Res; 2004 Aug; 2(8):453-63. PubMed ID: 15328372 [TBL] [Abstract][Full Text] [Related]
16. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030 [TBL] [Abstract][Full Text] [Related]
17. mTOR and P70 S6 kinase expression in primary liver neoplasms. Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621 [TBL] [Abstract][Full Text] [Related]
18. Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice. Zhang H; Kuang SQ; Liao L; Zhou S; Xu J Cancer Res; 2004 Oct; 64(19):7169-77. PubMed ID: 15466215 [TBL] [Abstract][Full Text] [Related]
19. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Wu Q; Kiguchi K; Kawamoto T; Ajiki T; Traag J; Carbajal S; Ruffino L; Thames H; Wistuba I; Thomas M; Vasquez KM; DiGiovanni J Cancer Res; 2007 Apr; 67(8):3794-800. PubMed ID: 17440093 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]